Wow--Big news. I've heard from a lot of concerned mental health providers about the risks of metabolic syndrome for individuals who are taking atypical antipsychotics for serious mental illnesses. Jack Carney, a retired case manager from New York City, blogged throughout 2011 on this topic, even recommending a "metabolic syndrome monitoring" program.
Looks like a study by researchers at Sanford-Burnham (La Jolla, Calif.) has finally found the mechanism that accounts for the change. Turns out, it's the same cellular pathway that's associated with diabetes--and certain atypicals trigger a key protein in this pathway that leads to metabolic symptoms.
So here's a question, if antipsychotic meds could be developed that would not cause metabolic syndrome, what would the impact be? Or, has the link between these meds and metabolic problems cast doubt on them forever? Will consumers taking these meds stop? What do you think will happen next?